1. Abendschein W, Hyatt G. Ultrasonic and selected physical properties of bone. Clin Orthop Relat Res 69: 294-301, 1970.
2. Agarwala N, Gay C. Specific binding of parathyroid hormone to living osteoclasts. J Bone Miner Res 7: 531-539, 1992.
3. Akhter M, Kimmel D, Recker R. Effect of parathyroid hormone (hPTH[1-84]) treatment on bone mass and strength in ovariectomized rats. J Clin Densitometry In press, 2000.
4. Akhter M, Raab D, Turner C, Kimmel D, Recker R. Characterization of in vivo strain in the rat tibia during external application of a four-point bending load. J Biomech 25: 1241-1246, 1992.
5. Alam A, Bax C, Shankar V, Bax B, Bevis P, Huang C-H, Moonga B, Pazianas M, Zaidi M.
Further studies on the mode of action of calcitonin on isolated rat osteoclasts:
pharmacological evidence for a second site mediating extracellular Ca2+ mobilization and cell retraction. J Endocrinol 136 (1): 7-15, 1993.
6. Albers M, Johnson W, Vivian V, Jackson R.
Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone 12: 39-42, 1991.
7. Allain T, Chambers T, Flanagan A, Mcgregor A. Tri-iodothyronine stimulates rat osteoclastic bone resorption by an indirect effect. J Endocrinol 133: 327-331, 1992.
8. Anderson P, Bondesson U, de Faire U.
Pharmacokinetics of verapamil in hypertension. Eur J Clin Pharmacol 31: 155-163, 1986.
9. Anonymous. Recommended methods for the determination of four enzymes in blood. Scand J Clin Lab Invest 33: 291-306, 1974.
10. Ashman R, Corin J, Turner C. Elastic properties of cancellous bone: Measurement by an ultrasonic technique. J Biomech 20 (10):
979-986, 1987.
11. Ashman R, Cowin S, Van Buskirk W, Rice J.
A continuous wave technique for the measurement of the elastic properties of cortical bone. J Biomech 17: 349-361, 1984.
12. Ashman R, Rho J. Elastic modulus of trabecular bone material. J Biomech 21 (3):
177-181, 1988.
13. Atkins G, Hayes D, Geary S, Loric M, Crotti T, Findlay D. Coordinated cytokine expression be stromal and hematopoietic cells during human osteoclast formation. Bone 26: 653-661, 2000.
14. Avioli L. Calcium and osteoporosis. Ann Rev Nutr 4: 471-491, 1984.
15. Balena R, Toolan B, Shea M, Markatos A, Myers E, Lee S, Opas E, Seedor J, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes W, Rodan G. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 2577-2586, 1993.
16. Baron R, Vignery A, Neff L, Silverglate A, Santa Maria A. Processing of undecalcified bone specimens for bone histomorphometry.
In: Recker R, ed. Bone Histomorphometry:
Techniques and Interpretation. Boca Raton:
CRC Press, pp. 13-35., 1983.
17. Bartels H, Brohmer M, Heierly C. Serum Kreatininbestimmung ohne Enteiweissen. Clin Chem Acta 37: 193-197, 1972.
18. Bauer D, Glüer C, Genant H, Stone K.
Quantitative ultrasound and vertebral fracture in postmenopausal women. Fracture Interventional Trial Research Group. J Bone Miner Res 10: 353-358, 1995.
19. Bauman B, Wronski T. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 16: 247-253, 1995.
20. Bianco P, Riminucci M, Bonocci E, Termine J, Robey P. Bone sialoprotein (BSP) secretion and osteoblast differentiation: Relationship to bromodeoxyuridine incorporation, alkaline phosphatase, and matrix deposition. J Histochem Cytochem 41: 183-191, 1993.
21. Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M, Bauer D, Genant H, Haskell W, Marcus R, Ott S, Torner J, Quandt S, Reiss T, Ensrud K. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
Fracture Intervention Trial Research Group.
Lancet 348: 1535-41, 1996.
22. Boesgaard S, Hyldestrup L, Feldstedt M.
Changes in calcium homeostasis and bone formation in patients recovering from acute myocardial infarction: Effect of verapamil treatment. The Danish Study Group on Verapamil in Myocardial Infarction. Eur J Clin Pharmacol 41: 521-523, 1991.
23. Bogin E, Chagnac A, Jüppner H, Levi J. Effect of verapamil on plasma parathyroid hormone.
J Clin Chem Clin Biochem 25: 83-85, 1987.
24. Breuer B, Wallenstein S, Anderson R. Effects of tamoxifen on bone fracture in older nursing home residents. J Am Geriatr Soc 46 (8): 968-972, 1998.
25. Brixen K, Nielsen H, Mosekilde L, Flyvbjerg A. A short course of rhGH stimulates osteoblasts and activates bone remodeling in normal volunteers. J Bone Miner Res 5: 609-618, 1990.
26. Buchwalter J, Glimcher M, Cooper R, Recker R. Bone biology. Part I. structure, blood supply, cells, matrix, and mineralization. Instr Course Lect 45: 371-386, 1996.
27. Burr D, Martin R. Mechanisms of bone adaptation to the mechanical environment.
Triangle 31 (2/3): 59-76, 1992.
28. Cann C. Quantitative CT for determination of bone mineral density: a review. Radiology 166: 509-522, 1988.
29. Cardona J, Pastor E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials. Osteoporos Int 7: 165-174, 1997.
30. Chagnac A, Gazit D, Zahavi I, Sela J, Levi J.
Effects of verapamil on bone resorption and formation in uremic rats. Miner Electrolyte Metab 15: 291-294, 1989.
31. Chang C, Kokontis J, Liao S. Structural analysis of complementary DNA and amino acid sequences of human and rats androgen receptors. Proc Natl Acad Sci USA 85 (19):
7211-7215, 1988.
32. Chapuy M, Arlot M, Delmas P, Meunier P.
Effect of calcium and cholacalciferol treatment for three years on hip fractures in elderly women. Br Med J 308: 1081-1082, 1994.
33. Cheng M, Zaman G, Rawlinson S, Suswillo R, Laynon L. Mechanical loading and sex hormone interactions in organ cultures of rat ulna. J Bone Miner Res 11 (4): 502-511, 1996.
34. Cheng P, Aye L, Vieth R, Muller K. Estrogen dose required to maintain parathyroid hormone mediated bone gain in osteopenic ovariectomized rats is probably higher than in preventive treatment with estrogen. Bone 17(Suppl. 4): 329S-334S, 1995.
35. Chesnoy-Marchais D, Fritsch J. Voltage-gated sodium and calcium currents in rat osteoblast.
J Physiol 398: 291-311, 1988.
36. Chesnut CH 3rd, McClung M, Ensrud K, Bell N, Genant H, Harris S, Singer F, Stock J, Yood R, Delmas P, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99 (2):
144-152, 1995.
37. Chow J, Jagger C, Chambers T.
Characterization of osteogenic response to mechanical stimulation in cancellous bone of rat caudal vertebrae. Am J Physiol 265: E340-E347, 1993.
38. Chow J, Tobias J, Colston K, Chambers T.
Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 89: 74-78, 1992.
39. Colvard D, Eriksen E, Keeting P, Wilson E, Lubahn D, French F, Riggs B, Spelsberg T.
Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 86 (3): 854-857, 1989.
40. Conover W. Practical nonparametric statistics.
2nd ed. New York: Wiley, 1980.
41. Cooper C, Melton L. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, pp. 419-34, 1996.
42. Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R. Estrogen protection against bone-resorbing effects of parathyroid hormone infusion. Ann Intern Med 118: 337-343, 1993.
43. Cowin S, Moss-Salentijn L, Moss M.
Candidates for the mechanosensory system in bone. J Biomed Eng 113: 191-197, 1991.
44. Crilly R, Francis R, Nordin B. Steroid hormones, ageing and bone. Clin Endocrinol Metab 10 (1): 115-139, 1981.
45. Cullum I, Ell P, Ryder J. X-ray dual photon absorptiometry: a new method for the measurement of bone density. Br J Radiol 62:
587-592, 1989.
46. Cummings S, Black D, Nevitt M, Browner W, Cauley J, Ensrud K, Genant H, Palermo L, Scott J, Vogt T. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.
Lancet 341 (8837): 72-75, 1993.
47. Cummings S, Kelsey J, Nevitt M, O'Dowd K.
Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7: 178-208, 1985.
48. Cummings S, Nevitt M, Browner W, Stone K, Fox K, Ensrud K, Cauley J, Black D, Vogt T.
Risk factors for hip fracture in white women.
Study of Osteoporotic Fractures Research Group. N Engl J Med 332 (12): 767-773, 1995.
49. Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott A, Hausherr E, Meunier P, Breart G. Fall-related factors and risk of hip fracture: the EPIDOS prospective study.
Lancet 348 (9021): 145-149, 1996.
50. de la Piedra C, Torres R, Rapado A, Diaz Curiel M, Castro N. Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 45 (1): 58-60, 1989.
51. Delmas P, Gineyts E, Bertholin A, Garnero P, F M. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 5: 643-648, 1993.
52. Doty S. Morphological evidence of gap junctions between bone cells. Calcif Tissue Int 33: 509-512, 1981.
53. Duncan R, Hruska K. Chronic, intermittent loading alters mechanosensitive channel characteristics in osteoblast-like cells. Am J Physiol 267: F909-F916, 1994.
54. Duncan R, Hruska K, Misler S. Parathyroid hormone activation of stretch-activated cation channels in osteosarcoma cells (UMR-106.01).
FEBS letter 307: 219-223, 1992.
55. Duncan R, Turner C. Mechanotransduction and the functional response of bone to mechanical strain. Calcif Tissue Int 57: 344-358, 1995.
56. Dunnett C. New tables for multiple comparisons with a control. Biometrics 20:
482-491, 1964.
57. Egan J, Gronowicz G, Rodan G. Parathyroid hormone promotes the disassembly of cytoskeleton actin and myosin in cultured osteoblastic cells: mediation by cAMP. J Cell Biochem 45: 101-111, 1991.
58. Ejersted C, Andreassen T, Hauge E, Melsen F, Oxlund H. Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 17: 507-511, 1995.
59. Ejersted C, Andreassen T, Nilsson M, Oxlund H. Human parathyroid hormone (1-34) increases bone formation and strength of cortical bone in aged rats. Eur J Endocrinol 130: 201-207, 1994.
60. Ejersted C, Andreassen T, Oxlund H, Jorgensen P, Bak B, Haggblad J, Tørring O, Nilsson M. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats.
J Bone Miner Res 8: 1097-1101, 1993.
61. Ejersted C, Oxlund H, Andreassen T.
Bisphosphonate maintains parathyroid hormone (1-34)-induced cortical bone mass and mechanical strength in old rats. Calcif Tissue Int 63: 316-322, 1998.
62. Ejersted C, Oxlund H, Eriksen E, Andreassen T. Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone 23: 43-52, 1998.
63. Epstein S. Postmenopausal osteoporosis:
fracture consequences and treatment efficacy vary by skeletal site. Aging 12 (5): 330-341, 2000.
64. Eriksen E, Axelrod D, Melsen F. The cellular basis of bone remodeling. In: Bone histomorphometry. New York: Raven Press, pp. 13-20, 1994.
65. Eriksen E, Colvard D, Berg N, Graham M, Mann K, Spelsberg T, Riggs B. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241: 84-86, 1988.
66. Eriksen E, Gundersen H, Melsen F, Mosekilde L. Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Relat Res 5: 243-252, 1984.
67. Ernst M, Heath J, Rodan G. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I,
and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 125:
825-833, 1989.
68. Eskandar E, Kimmel D, Wronski T. Rapid determination of cancellous bone mineral loss in ovariectomized rats by a subtraction technique. Anat Rec 230: 169-174, 1991.
69. Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H, Christiansen C, Delmas P, Zanchetta J, Stakkestad J, Glüer C, Krueger K, Cohen F, Eckert S, Ensrud K, Avioli L, Lips P, Cummings S. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (7): 637-645, 1999.
70. Ettinger B, Genant H, Cann C. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102: 319-324, 1985.
71. Evans G, Bryant H, Magee D, Sato M, Turner R. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Endocrinology 134 (5): 2283-2288, 1994.
72. Eyre D, Koob T, Van Ness K. Quantitation of hydoxypyridinium crosslinks in collagen by high-performance liquid chromatography.
Anal Biochem 137: 380-388, 1984.
73. Farley J, Chesnut J, Baylink D. Improved method for quantitative determination in serum alkaline phosphatase of skeletal origin.
Clin Chem 27: 2002-2007, 1981.
74. Farley S, Libanati C, Mariano-Menez M, Tudtud-Hans L, Schulz E, Baylink D. Fluoride therapy for osteoporosis promotes a progressive increase in spinal bone density. J Bone Miner Res 5(Suppl. 1): S37-S42, 1990.
75. Fisher J, Rodan G, Reszka A. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141 (12):
4793-4896, 2000.
76. Fleckenstein A. Specific inhibitors and promotors of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie L, eds.
Calcium and the heart. New York: Academic Press, pp. 135-138, 1971.
77. Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos Int 6: 166-170, 1996.
78. Fleisch H. Bisphosphonates: Mechanisms of action. Endocrine Rev 19 (1): 80-100, 1998.
79. Fox J, Della-Santina C. Oral verapamil and calcium and vitamin D metabolism in rats:
effect of dietary calcium. Am J Physiol 257:
E632-E638, 1989.
80. Fox J, Green D. Direct effects of calcium channel blockers on duodenal calcium transport in vivo. Eur J Pharmacol 129: 159-164, 1986.
81. Fritsch J, Cesnoy-Marchais D. Dual modulation of the L-type calcium current of rat osteoblastic cells by parathyroid hormone:
Opposite effects of protein kinase C and cyclic nucleotides. Cell Signal 6: 645-655, 1994.
82. Frost H. Bone histomorphometry: Analysis of trabecular bone dynamics. In: Recker R, ed.
Bone Histomorphometry: Techniques and Interpretation. Boca Raton: CRC Press, pp.
109-142, 1983.
83. Frost H. Bone "mass" and the "mechanostat":
a proposal. Anat Rec 219: 1-9, 1987.
84. Frost H. A determinant of bone architecture.
The minimum effective strain. Clin Orthop 200: 198-225, 1983.
85. Frost H. Tetracycline-base histological analysis of bone remodeling. Calcif Tissue Int 3: 211-237, 1969.
86. Frost H, Schönau E. The "muscle-bone unit"
in children and adolescents: A 2000 overview.
J Pediatr Endocrinol Metab 13 (6): 571-590, 2000.
87. Garnero P, Delmas P. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77 (4): 1046-1053, 1993.
88. Gasser A, Morgan D, Fleisch H, Richelle L.
The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43: 31-45, 1972.
89. Gindler E, King J. Rapid colorometric determination of calcium in biologic fluids with methylthymol blue. Am J Clin Pathol 58:
376-382, 1972.
90. Glüer C, Wu C, Genant H. Broadband ultrasound attenuation signals depend on trabecular orientation: an in vitro study.
Osteoporos Int 3: 185-191, 1993.
91. Goldner J. Modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14: 237-243, 1938.
92. Gray T, Flynn T, Gray K, Nabell L. 17beta-estradiol acts directly on the clonal osteoblastic cell line UMR106. Proc Natl Acad Sci USA 84 (17): 6267-6271, 1987.
93. Guggino S, Lajeunesse D, Wagner J, Snyder S. Bone remodeling signaled by a dihydropyridine- and phenylalkamine-sensitive calcium channel. Proc Natl Acad Sci 86: 2957-2960, 1989.
94. Guggino S, Wagner J, Snowman A, Hester L, Sacktor B, Snyder S. Phenylalkylamine-sensitive calcium channels in osteoblast-like osteosarcoma cells. J Biol Chem 263: 10155-10161, 1988.
95. Gunness-Hey M, Hock J. Loss of the anabolic effect of PTH on bone after discontinuation of hormone in rats. Bone 10: 447-452, 1989.
96. Hagino H, Raab D, Kimmel D, Akhter M, Recker R. Effect of ovariectomy on bone response to in vivo external loading. J Bone Miner Res 8: 347-357, 1993.
97. Halme J, Uitto J, Kivirikko K, Saxen L, 1972.
Effect of triiodothyronine in the metabolism of collagen in cultured embryonic bones.
Endocrinology 90: 1476-1482, 1972.
98. Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen E, Hoseyni M, Axelrod D.
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
JAMA 282 (14): 1344-1352, 1999.
99. Harris S, Watts N, Jackson R, Genant H, Wasnich R, Ross P, Miller P, Licata A, Chesnut CH 3rd. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95 (6): 557-567, 1993.
100. Heath J, Atkinson S, Meikle M, Reynolds J.
Mouse osteoblasts synthesize collagenase in response to bone resorbing agents. Biochem Biophys Acta 802: 151-154, 1984.
101. Hemenway D, Colditz G, Willett W, Stampfer M, Speizer F. Fractures and lifestyle: effects of cigarette smoking, alcohol intake, and relative weight on the risk of hip and forearm fractures in middle-age women. Am J Public Health 78:
1554-1558, 1988.
102. Henry H. Vitamin D hydroxylases. J Cell Biochem 49: 4-9, 1992.
103. Herrman-Erlee M, Gaillard P, Hekkelman J, Nijweide P. The effect on the action of parathyroid hormone on embryonic bone in vitro. Eur J Pharmacol 46: 51-58, 1977.
104. Herrman-Erlee M, Heersche J, Hekkelman J, Gaillard P, Tregear G, Parsons J, Potts JT Jr.
Effects of bone in vitro of bovine parathyroid hormone, synthetic fragments representing residues 1-34, 2-34, 3-34. Endocr Res Commun 3 (1): 21-35, 1976.
105. Hock J, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication.
Endocrinology 122: 254-260, 1988.
106. Hock J, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7: 65-72, 1992.
107. Hock J, Hummert J, Boyce R, Fonseca J, Raisz L. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J Bone Miner Res 4: 449-458, 1989.
108. Hodsman A, Fraher L, Watson P, Ostbye T, Stitt L, Adachi J, Taves D, Drost D. A randomized controlled trial to compare the
efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82: 620-628, 1997.
109. Hughes D, MacDonald B, Russel R, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83: 1930-1935, 1989.
110. Hughes D, Wright K, Uy H, Sasaki A, Yoneda T, Roodman G, Mundy G, Boyce B.
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487, 1995.
111. Hutchinson T, Polansky S, Feinstein A.
Postmenopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet 2: 705-709, 1979.
112. Hvarfner A, Bergström R, Lithell H, Mörlin C, Wide L, Ljunghall S. Changes in calcium metabolic indices during long-term treatment of patients with essential hypertension. Clin Sci 75: 543-549, 1988.
113. Johnell O, Gullberg B, Kanis J, Allander E, Elffors L, Dequeker J, Dilsen G, Gennari C, Lopes Vaz A, Lyritis G, et al. Risk factor for hip fracture in European women: the MEDOS study. Mediterranean Osteoporosis Study. J Bone Miner Res 10 (11): 1802-1815, 1995.
114. Johnston CC Jr, Bjarnason N, Cohen F, Shah A, Lindsay R, Mitlak B, Huster W, Draper M, Harper K, Heath H 3rd, Gennari C, Christiansen C, Arnaud C, Delmas P. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160 (22): 3444-3450, 2000.
115. Jones D, Nolte H, Scholubbers J-G, Turner E, Veltel D. Biochemical signal transduction of mechanical strain in osteoblast-like cells.
Biomaterials 12: 101-110, 1991.
116. Jones G, Nguyen T, Sambrook P, Kelly P, Eisman J. Progressive loss of bone in femoral neck in elderly people: Longitudinal findings from the Dubbo Osteoporosis Epidemiology Study. Br Med J 309: 691-695, 1994.
117. Kalu D. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15 (3):
175-191, 1991.
118. Kanis J. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report.
WHO Study Group. Osteoporos Int 4 (6): 368-381, 1994.
119. Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Järvinen M, Vuori I. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 343 (21): 1506-1513, 2000.
120. Karpf D, Shapiro D, Seeman E, Ensrud K, Johnston C Jr, Adami S, Harris S, Santora A 2nd, Hirsch L, Oppenheimer L, Thompson D.
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277: 1159-64, 1997.
121. Kasperk C, Wergedal J, Farley J, Linkhart T, Turner R, Baylink D. Androgens directly stimulate proliferation of bone cells in vitro.
Endocrinology 124: 1576-1578, 1989.
122. Kassem M, Mosekilde L, Eriksen E. Effects of triiodothyroidine on DNA synthesis and differentiation markers of normal human osteoblast-like cells in vitro. Biochem Mol Biol Int 30 (4): 779-788, 1993.
123. Keeting P, Scott R, Colvard D, Han I, Spelsberg T, Riggs B. Lack of direct effect of estrogen on proliferation and differentiation of normal human osteoblast-like cells. J Bone Miner Res 6: 297-304, 1991.
124. Keshawarz N, Recker R. Expansion of the medullary cavity at the expense of the cortex in postmenopausal osteoporosis. Metab Bone Dis Relat Res 5: 223-228, 1984.
125. Kim Y, Yang I, Kim S, Kim J, Kim K, Choi Y. Response of osteoblastic cell line MC3T3-E1 cell to the calcium channel blocker diltiazem and verapamil. Vol. 91, pp. 43-49, 1991.
126. Kimmel D, Bozzato R, Kronis K, Coble T, Sindrey D, Kwong P, Recker R. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult, osteopenic, ovariectomized rats.
Endocrinology 132: 1577-1584, 1993.
127. Kimmel D, Recker R, Gallagher J, Vaswani A, Aloia J. A comparison of iliac bone histomorphometry in post-menopausal osteoporotic and normal subjects. Bone Miner 11: 217-235, 1990.
128. Kimmel D, Wronski T. Non-destructive measurement of bone mineral in femurs from ovariectomized rats. Calcif Tissue Int 46: 101-110, 1990.
129. Kishi T, Hagino H, Kishimoto H, Nagashima H. Bone responses at various skeletal sites to human parathyroid hormone in ovariectomized rats: Effects of long-term administration, withdrawal, and readministration. Bone 22:
515-522, 1998.
130. Kleerekoper M, Villanueva A, Stanciu J, Rao D, Parfitt A. The role of three dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37: 594-597, 1985.
131. Klein-Nulend J, Van der Plas A, Semeins C, Ajubi N, Frangos J, Nijweide P, Burger E.
Sensitivity of osteocytes to biomechanical stress in vivo. FASEB 9: 441-445, 1995.
132. Krane S, Kantrowitz F, Byrne M, Pinnel S, Singer F. Urinary excretion of hydroxylysine
and its glycosides as an index of collagen degradation. J Clin Invest 59: 819-827, 1977.
133. Lane N, Thompson J, Strewler G, Kinney J.
Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res 10: 1470-1477, 1995.
134. Laugier P, Giat P, Berger G. Broadband ultrasonic attenuation imaging: a new imaging technique of the os calcis. Calcif Tissue Int 54:
83-86, 1994.
135. Laynon L, Rubin C. Static versus dynamic loads as an influence on bone remodeling. J Biomech 17: 897-906, 1984.
136. Lerner U, Fredholm B, Hänström L.
Diphenylhydantoin inhibits parathyroid hormone and prostaglandin E2-stimulated bone resorption in mouse calvaria without affecting cyclic AMP formation. J Oral Pathology 14: 644-653, 1985.
137. Lerner U, Gustafson G. Inhibition of 1alpha-hydroxy-vitamin D3 stimulated bone resorption in tissue culture by the calcium antagonist verapamil. Eur J Clin Invest 12:
185-190, 1982.
138. Li M, Mosekilde L, Søgaard C, Thomsen J, Wronski T. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 16: 629-635, 1995.
139. Li M, Wronski T. Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 16: 551-557, 1995.
140. Libanati C, Lau K, Baylink D. Fluoride therapy for osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, pp. 1259-1277, 1996.
141. Liberman U, Weiss S, Bröll J, Minne H, Quan H, Bell N, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 (22): 1437-1443, 1995.
142. Lieberherr M. Effects of vitamin D3 metabolites on cytosolic free calcium in confluent mouse osteoblasts. J Biol Chem 262:
13168-13173, 1987.
143. Lieberherr M, Grosse B. Androgens increase intracellular calcium concentrations and inositol 1,4,5-triphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem 269 (1o): 7217-7223, 1994.
144. Lieberherr M, Grosse B, Kachkache M, Balsan S. Cell signaling and estrogens in female rat osteoblasts: A possible involvement of unconventional nonnuclear receptors. J Bone Miner Res 8: 1365-1376, 1993.
145. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shan V, Dempster D, Cosman F.
Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350: 550-555, 1997.
146. Linkhart S, Linkhart T, Taylor A, Wergedal J, Bettica P, Baylink D. Synthetic peptide-based immunoassey for amino-terminal propeptide of type I procollagen: Application for evaluation of bone formation. Clin Chem 39:
2254-2258, 1993.
147. Liu C, Kalu D, Salerno E, Echon R, Hollis B, Ray M. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J Bone Miner Res 6: 1071-1080, 1991.
148. Lukert B, Kream B. Clinical and basic aspects of glucocorticoid action in bone. In: Bilezikian J, Raisz L, Rodan G, eds. Principles of bone biology. San Diego: Academic Press, pp. 533-548, 1996.
149. Ma Y, Ferretti J, Capozza R, Cointry G, Alippi R, Zanchetta J, Jee W. Effects of on/off anabolic hPTH and remodeling inhibitors on metaphyseal bone of immobilized rat femurs.
Tomographical (pQCT) description and correlation with histomorphometric changes in tibial cancellous bone. Bone 17: 321S-327S, 1995.
150. Ma Y, Jee W, Chen Y, Gasser J, Ke H, Li X, Kimmel D. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. J Bone Miner Res 10: 1726-1734, 1995.
151. Mark M, Butler W, Prince C, Finkelman R, Ruch J. Developmental expression of 44-kDa bone phosphoprotein (osteopontin) and bone gamma-carboxyglutamic acid (gla) containing protein (osteocalcin) in calcifying tissues of rat. Differentiation 37 (2): 123-136, 1988.
152. Marks SC Jr. The origin of osteoclasts:
Evidence, clinical implications and investigative challenges of an extra-skeletal source. J Oral Pathology 12: 226-256, 1983.
153. Marks SC Jr, Hermey D. The structure and development of bone. In: Bilezikian J, Raisz L, Rodan G, eds. Principles of bone biology. San Diego: Academic Press, pp. 3-14, 1996.
154. Martin D, DeLuca H. Influence of sodium on calcium transport by the rat small intestine.
Am J Physiol 216: 1351-1359, 1969.
155. Mazess R, Collick B, Trempe J, Barden H, Hanson J. Performance evaluation of a dual-energy x-ray bone densitometer. Calcif Tissue Int 44: 228-232, 1989.
156. McSheehy P, Chambers T. 1,25-dihydroxyvitamin D3 stimulates rat osteoblastic cells to release a soluble factor that increases osteoclastic bone resorption. J Clin Invest 80: 425-429, 1987.